Shares of Nektar Therapeutics (NASDAQ:NKTR) gained on Friday after Jefferies upgraded the stock noting an attractive ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Ratings reports. One equities ...

Jefferies upgraded Nektar (NKTR) to Buy from Hold with a price target of $2, up from $1. The company’s rezpegaldesleukin will report topline ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders.

In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6 ...

Zacks Research boosted their Q1 2025 earnings per share estimates for Nektar Therapeutics in a research note issued on ...